HRP20030098A2 - Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma - Google Patents
Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma Download PDFInfo
- Publication number
- HRP20030098A2 HRP20030098A2 HR20030098A HRP20030098A HRP20030098A2 HR P20030098 A2 HRP20030098 A2 HR P20030098A2 HR 20030098 A HR20030098 A HR 20030098A HR P20030098 A HRP20030098 A HR P20030098A HR P20030098 A2 HRP20030098 A2 HR P20030098A2
- Authority
- HR
- Croatia
- Prior art keywords
- fraction
- mentioned
- treatment
- lipid
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 77
- 238000011282 treatment Methods 0.000 title claims description 77
- 210000002381 plasma Anatomy 0.000 title claims description 50
- 238000000034 method Methods 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 16
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 9
- 238000003745 diagnosis Methods 0.000 title description 6
- 150000002632 lipids Chemical class 0.000 title description 2
- 239000000126 substance Substances 0.000 claims description 61
- 210000004369 blood Anatomy 0.000 claims description 39
- 239000008280 blood Substances 0.000 claims description 38
- 241000283690 Bos taurus Species 0.000 claims description 20
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 238000005119 centrifugation Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical group O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 238000001962 electrophoresis Methods 0.000 claims description 2
- 244000144972 livestock Species 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 210000003371 toe Anatomy 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 241000306001 Cetartiodactyla Species 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 229940127090 anticoagulant agent Drugs 0.000 claims 1
- 208000011581 secondary neoplasm Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 47
- 230000004083 survival effect Effects 0.000 description 45
- 238000002474 experimental method Methods 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 28
- 230000000694 effects Effects 0.000 description 22
- 239000013641 positive control Substances 0.000 description 18
- 239000000306 component Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 238000010586 diagram Methods 0.000 description 13
- 230000006872 improvement Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000002513 implantation Methods 0.000 description 10
- 206010000830 Acute leukaemia Diseases 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102000004008 5'-Nucleotidase Human genes 0.000 description 8
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 8
- 230000001133 acceleration Effects 0.000 description 6
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 5
- 230000002349 favourable effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 208000003747 lymphoid leukemia Diseases 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000005741 malignant process Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 108010002712 deoxyribonuclease II Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004066 metabolic change Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000001875 tumorinhibitory effect Effects 0.000 description 2
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000295146 Gallionellaceae Species 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 241000557766 Guthriea Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920004011 Macrolon® Polymers 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710113020 Ornithine transcarbamylase, mitochondrial Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0002597A HUP0002597A2 (hu) | 2000-07-10 | 2000-07-10 | Gyógyászati készítmény, elsősorban tumoros megbetegedések gyógyítására és diagnosztizálására és eljárás vérplazma lipidmentes frakciójának előállítására |
| PCT/HU2001/000078 WO2002007739A2 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20030098A2 true HRP20030098A2 (en) | 2004-08-31 |
Family
ID=89978459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20030098A HRP20030098A2 (en) | 2000-07-10 | 2003-02-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20040253317A1 (ru) |
| EP (1) | EP1333844A2 (ru) |
| JP (1) | JP2004504353A (ru) |
| KR (1) | KR20030016392A (ru) |
| CN (1) | CN1477965A (ru) |
| AU (1) | AU2001277630A1 (ru) |
| BG (1) | BG107547A (ru) |
| BR (1) | BR0112866A2 (ru) |
| CA (1) | CA2415862A1 (ru) |
| EA (1) | EA005415B1 (ru) |
| HR (1) | HRP20030098A2 (ru) |
| HU (1) | HUP0002597A2 (ru) |
| IL (1) | IL153867A0 (ru) |
| MX (1) | MXPA03000342A (ru) |
| PL (1) | PL361049A1 (ru) |
| SK (1) | SK1282003A3 (ru) |
| WO (1) | WO2002007739A2 (ru) |
| YU (1) | YU9903A (ru) |
| ZA (1) | ZA200300675B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0200172A2 (hu) | 2002-01-15 | 2003-11-28 | András Bertha | Eljárás tumorellenes hatóanyag kinyerésére |
| GB2405540B (en) * | 2003-08-27 | 2006-05-10 | Ron Shu-Yuen Hui | Apparatus and method for providing dimming control of lamps and electrical lighting systems |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB791142A (en) * | 1954-09-22 | 1958-02-26 | Atsuwo Ushiyama | A process for preparing antibiotic substance from special bacterium in human blood plasma and earth |
| GB834256A (en) * | 1955-08-18 | 1960-05-04 | Olin Mathieson | Therapeutic bone mixture |
| US3083194A (en) * | 1959-05-18 | 1963-03-26 | Thies Karl | Montmorillonite adsorption of fibrin from bovine blood plasma |
| JPS5357191A (en) * | 1976-11-04 | 1978-05-24 | Asahi Chem Ind Co Ltd | Activated carbon for adsorption of toxin in serum |
| NL9001087A (nl) * | 1990-05-07 | 1991-12-02 | Harimex Ligos Bv | Werkwijze voor het zuiveren van bloedplasma. |
| RO111332B1 (ro) * | 1991-06-17 | 1996-09-30 | Inst De Cercetari Chimico Farm | Procedeu de obținere a unui produs hepatoprotector |
| HUP9900045A3 (en) * | 1999-01-08 | 2001-02-28 | Martyn Robertne Goeroeg Jolan | Improved leukaemic blood-based product and their use in therapy |
-
2000
- 2000-07-10 HU HU0002597A patent/HUP0002597A2/hu unknown
-
2001
- 2001-07-10 SK SK128-2003A patent/SK1282003A3/sk unknown
- 2001-07-10 WO PCT/HU2001/000078 patent/WO2002007739A2/en not_active Application Discontinuation
- 2001-07-10 US US10/332,440 patent/US20040253317A1/en not_active Abandoned
- 2001-07-10 JP JP2002513472A patent/JP2004504353A/ja active Pending
- 2001-07-10 KR KR10-2003-7000393A patent/KR20030016392A/ko not_active Application Discontinuation
- 2001-07-10 EA EA200300133A patent/EA005415B1/ru not_active IP Right Cessation
- 2001-07-10 PL PL01361049A patent/PL361049A1/xx unknown
- 2001-07-10 IL IL15386701A patent/IL153867A0/xx unknown
- 2001-07-10 EP EP01955468A patent/EP1333844A2/en not_active Withdrawn
- 2001-07-10 CN CNA018139744A patent/CN1477965A/zh active Pending
- 2001-07-10 BR BRPI0112866 patent/BR0112866A2/pt not_active Application Discontinuation
- 2001-07-10 AU AU2001277630A patent/AU2001277630A1/en not_active Abandoned
- 2001-07-10 MX MXPA03000342A patent/MXPA03000342A/es unknown
- 2001-07-10 YU YU9903A patent/YU9903A/sh unknown
- 2001-07-10 CA CA002415862A patent/CA2415862A1/en not_active Abandoned
-
2003
- 2003-01-24 ZA ZA200300675A patent/ZA200300675B/xx unknown
- 2003-02-10 HR HR20030098A patent/HRP20030098A2/hr not_active Application Discontinuation
- 2003-02-10 BG BG107547A patent/BG107547A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2415862A1 (en) | 2002-01-31 |
| US20040253317A1 (en) | 2004-12-16 |
| MXPA03000342A (es) | 2004-12-13 |
| IL153867A0 (en) | 2003-07-31 |
| PL361049A1 (en) | 2004-09-20 |
| SK1282003A3 (en) | 2003-08-05 |
| HU0002597D0 (en) | 2000-09-28 |
| ZA200300675B (en) | 2004-02-19 |
| WO2002007739A3 (en) | 2002-10-10 |
| EP1333844A2 (en) | 2003-08-13 |
| JP2004504353A (ja) | 2004-02-12 |
| BG107547A (bg) | 2004-01-30 |
| WO2002007739A2 (en) | 2002-01-31 |
| YU9903A (sh) | 2006-05-25 |
| AU2001277630A1 (en) | 2002-02-05 |
| HUP0002597A2 (hu) | 2003-01-28 |
| CN1477965A (zh) | 2004-02-25 |
| EA200300133A1 (ru) | 2003-06-26 |
| WO2002007739A9 (en) | 2003-10-16 |
| KR20030016392A (ko) | 2003-02-26 |
| BR0112866A2 (ru) | 2009-12-08 |
| EA005415B1 (ru) | 2005-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69633668T2 (de) | Allogene zelltherapie für krebs infolge allogener stammzellen transplantation | |
| Willcox et al. | Autologous peripheral blood hematopoietic cell transplantation in dogs with B‐cell lymphoma | |
| KR20130033354A (ko) | Ｎｋ세포 강화형 혈액제제의 제조 방법 | |
| WO2007056852A1 (en) | Compositions of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer | |
| Warry et al. | Autologous peripheral blood hematopoietic cell transplantation in dogs with T‐cell lymphoma | |
| Skopinska-Rozewska et al. | Inhibitory effect of shark liver oil on cutaneous angiogenesis induced in Balb/c mice by syngeneic sarcoma L-1, human urinary bladder and human kidney tumour cells. | |
| JP2021165292A (ja) | 造血器腫瘍治療剤、およびスクリーニング方法 | |
| US20130121979A1 (en) | Method of treating cancer using platelet compositions | |
| JP6286445B2 (ja) | がんの治療のためのワクチン及びワクチン有効性を増強するための組成物 | |
| HRP20030098A2 (en) | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma | |
| CA3220057A1 (en) | Compositions and cell culture media for increasing neutrophil lifespan | |
| Winter et al. | Renal cell carcinoma and natural killer cells: studies in a novel rat model in vitro and in vivo | |
| Jurin et al. | Natural History of Mouse Syngeneic Lymphoma: Morphologic and Immunologic Aspects | |
| EP3328495A1 (en) | Methods and compositions for characterization of glioblastoma multiforme tumors and cancer stem cells | |
| US20060121449A1 (en) | Method for selection of compounds which inhibit clonal cell growth and use thereof | |
| WO2015179287A2 (en) | Z cells activated by zinc finger-like protein and uses thereof in cancer treatment | |
| Bond et al. | Acute whole body radiation injury: pathogenesis, pre-and postradiation protection | |
| RU2491060C1 (ru) | Способ нормализации спонтанной агрегации эритроцитов у свиноматок с артритом | |
| CN114222814A (zh) | 具有比人外周血的自然杀伤细胞更高水平的自然细胞毒性受体、杀伤活性及γ-干扰素生产能力的记忆样自然杀伤细胞的制备方法 | |
| Johnson et al. | Enhancement of mouse natural killer cell activity after dearterialization of experimental renal tumors | |
| CN118490839A (zh) | 经典单核细胞在制备靶向治疗神经胶质瘤的纳米药物中的应用 | |
| DeVita | Cancer Treatment | |
| Gee | Studies on mechanisms of genetic resistance to a lethal virus infection | |
| Wilson et al. | ACTIVE ENHANCEMENT OF RAT RENAL ALLOGRAFTS BY SOLUBLE SPECIFIC ANTIGEN | |
| Johnson | Bactericidal Activity of Fixed and Circulating Phagocytes in Murine Radiation Chimeras Compared with Those from Unirradiated Mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| OBST | Application withdrawn |